Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 3
Novel Combination Regimens for 2L mCRC: Insights from ASCO 202 July 3, 2024
John Marshall, MD , Al B. Benson III, MD, FACP, FACCC, FASCO , Kristen Ciombor, MD, MSCI , Stacey A. Cohen, MD , Marwan Fakih, MD
The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.
Dr Cohen:ZL-IRIAN study (NCT05229003; Wang C, et al. ASCO 2024. Abstract 3570)– Irinotecan plus anlotinib ± penpulimab in 2L mCRC Dr Ciombor: Ph II study (Zhao W, et al. ASCO 2024. Abstract 3571) – fruquintinib plus investigator choice of chemotherapy in 2L mCRC